Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Oral Tamsulosin 0.4 mg ER Tablets in Healthy Males
NCT07698275Completed
- Sponsor
- Adium Pharma
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Randomised, open-label trial of tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Adium Pharma. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours and Area Under the Concentration-Time Curve From Time Zero to Time t at 72 hours. Started Jan 2026; status: completed.
02
Drugs
tamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT07698275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07698275.